Subscribe to RSS
DOI: 10.1055/a-1449-5027
Update 2021: COVID-19 aus Sicht der Kardiologie
Update 2021: COVID-19 from the perspective of cardiology
Vor über einem Jahr hat sich COVID-19 in rasanter Geschwindigkeit weltweit pandemisch ausgebreitet. Mit der großen Zahl an Erkrankten hat sich auch unser Wissen über SARS-CoV-2 in Bezug auf Krankheitsentstehung, Verlauf und therapeutische Möglichkeiten rasant entwickelt. Angesichts wieder steigender Fallzahlen im Rahmen der „dritten Welle“ möchten wir in diesem Beitrag COVID-19 aus aktualisierter kardiologischer Sicht erneut beleuchten und neue Erkenntnisse präsentieren.
Abstract
More than one year ago COVID-19 emerged to a rapidly expanding global pandemic. Along with a growing number of individuals infected with SARS-CoV-2, we gained substantial knowledge on development, progression and treatment of the disease. In the light of increasing worldwide infection rates during the current “third wave”, we will give a short update on COVID-19 from a cardiological point-of-view.
Publication History
Article published online:
13 July 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-1062
- 2 Giustino G, Croft LB, Oates CP. et al. Takotsubo Cardiomyopathy in COVID-19. J Am Coll Cardiol 2020; 76: 628-629
- 3 Zheng YY, Ma YT, Zhang JY. et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020; 17: 259-260
- 4 Tavazzi G, Pellegrini C, Maurelli M. et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail 2020; 22: 911-915
- 5 Modin D, Claggett B, Sindet-Pedersen C. et al. Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction. Circulation 2020; 142: 2080-2082
- 6 Nicolai L, Leunig A, Brambs S. et al. Vascular neutrophilic inflammation and immunothrombosis distinguish severe COVID-19 from influenza pneumonia. J Thromb Haemost 2021; 19: 574-581
- 7 Reynolds HR, Adhikari S, Pulgarin C. et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med 2020; 382: 2441-2448
- 8 Medcalf RL, Keragala CB, Myles PS. Fibrinolysis and COVID-19: A plasmin paradox. J Thromb Haemost 2020; 18: 2118-2122
- 9 Hill JB, Garcia D, Crowther M. et al. Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study. Blood Adv 2020; 4: 5373-5377
- 10 Bowles KH, McDonald M, Barron Y. et al. Surviving COVID-19 After Hospital Discharge: Symptom, Functional, and Adverse Outcomes of Home Health Recipients. Ann Intern Med 2021; 174: 316-325
- 11 Schultz NH, Sorvoll IH, Michelsen AE. et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021;
- 12 Greinacher A, Thiele T, Warkentin TE. et al. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med 2021;
- 13 Thachil J, Tang N, Gando S. et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020; 18: 1023-1026
- 14 Group WHOREAfC-TW, Sterne JAC, Murthy S. et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA 2020; 324: 1330-1341
- 15 Consortium WHOST, Pan H, Peto R. et al. Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results. N Engl J Med 2021; 384: 497-511
- 16 Simonovich VA, Burgos Pratx LD, Scibona P. et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med 2021; 384: 619-629